North ChicagoAbbVie paid $10.9B for Apogee’s interleukin-13-blocking drug.
Zumilokibart targets an inflammatory cytokine with 2-4 annual doses — designed to backfill AbbVie’s immunology portfolio as Humira’s patents expire.
Ongoing Phase 3 trials in atopic dermatitis and asthma determine when AbbVie can file for regulatory approval.
Sources: STAT